Sleep changes following statin therapy: A systematic review and meta-analysis of randomized placebo-controlled polysomnographic trials

Archives of Medical Science

Volumn 11, Issue 5, 2015, Pages 915-926

  Broncel, Marlena ^a   Gorzelak Pabis, Paulina ^a   Sahebkar, Amirhossein ^b,c   Serejko, Katarzyna ^a   Ursoniu, Sorin ^d   Rysz, Jacek ^a   Serban, Maria Corina ^d,e   Mozdzan, Monika ^a   Banach, Maciej ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Meta analysis; Polysomnography; Sleep; Stain therapy; Statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AROUSAL; EFFECT SIZE; HUMAN; LATENT PERIOD; MEDLINE; META ANALYSIS; POLYSOMNOGRAPHY; PUBLISHING; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCOPUS; SLEEP DISORDER; SLEEP STAGE; SLEEP TIME; SYSTEMATIC REVIEW; TREATMENT DURATION; WAKEFULNESS;

EID: 84944048085     PISSN: 17341922     EISSN: 18969151     Source Type: Journal    
DOI: 10.5114/aoms.2015.54841     Document Type: Review

References (35)

1. Catapano AL, Reiner Ž, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011; 217: 1-44.
2. Banach M, Rizzo M, Toth PP, et al. Statin intolerance -An attempt at a unified definition. Position paper from an International Lipid Expert Panel. Expert Opin Drug Saf 2015; 14: 935-55.
3. Banach M, Rizzo M, Toth PP, et al. Statin intolerance -An attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci 2015; 11: 1-23.
4. Banach M, Malodobra-Mazur M, Gluba A, Katsiki N, Rysz J, Dobrzyn A. Statin therapy and new-onset diabetes: Molecular mechanisms and clinical relevance. Curr Pharm Des 2013; 19: 4904-12.
5. Golomb BA, Evans MA, Dimsdale JE, White HL. Effects of statins on energy and fatigue with exertion: Results from a randomized controlled trial. Arch Intern Med 2012; 172: 1180-2.
6. Tuccori M, Lapi F, Testi A, et al. Statin-Associated psychiatric adverse events. Drug Safety 2008; 31: 1115-23.
7. Boriani G, Biffi M, Strocchi E, Branzi A. Nightmares and sleep disturbances with simvastatin and metoprolol. Ann Pharmacother 2001; 35: 1292.
8. Takada M, Fujimoto M, Yamazaki K, Takamoto M, Hosomi K. Association of statin use with sleep disturbances: Data mining of a spontaneous reporting database and a prescription database. Drug Safety 2014; 37: 421-31.
9. Vgontzas AN, Kales A, Bixler EO, Manfredi RL, Tyson KL. Effects of lovastatin and pravastatin on sleep efficiency and sleep stages. Clin Pharmacol Therap 1991; 50: 730-7.
10. Harrison R, Ashton C. Do cholesterol-lowering agents affect brain activity? A comparison of simvastatin, pravastatin, and placebo in healthy volunteers. Br J Clin Pharmacol 1994; 37: 231-6.
11. Barth JD, Kruisbrink O, Van Dijk AL. Inhibitors of hydroxymethylglutaryl coenzyme A reductase for treating hypercholesterolaemia. BMJ 1990; 301: 669.
12. Eckernäs S, Roos B, Kvidal P, et al. The effects of simvastatin and pravastatin on objective and subjective measures of nocturnal sleep: A comparison of two structurally different HMG CoA reductase inhibitors in patients with primary moderate hypercholesterolaemia. Br J Clin Pharmacol 1993; 35: 284-9.
13. Carlsson CM, Papcke-Benson K, Carnes M, McBride PE, Stein JH. Health-related quality of life and long-Term therapy with pravastatin and tocopherol (vitamin E) in older adults. Drugs Aging 2002; 19: 793-805.
14. Saheki A, Terasaki T, Tamai I, Tsuji A. In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. Pharmaceut Res 1994; 11: 305-11.
15. Tobert JA, Leslie B, Schaefer E, et al. HMG-CoA reductase inhibitors for hypercholesterolemia. N Engl J Med 1988; 319: 1222-3.
16. Hsia J, MacFadyen JG, Monyak J, Ridker PM. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol
17. Ditschuneit H, Kuhn K. Comparison of different HMGCoA reductase inhibitors. Eur J Clin Pharmacol 1991; 40: S27-32.
18. Roth T, Richardson GR, Sullivan JP, Lee RM, Merlotti L, Roehrs T. Comparative effects of pravastatin and lovastatin on nighttime sleep and daytime performance. Clin Cardiol 1992; 15: 426-32.
19. Kostis JB, Rosen RC, Wilson AC. Central nervous system effects of HMG CoA reductase inhibitors: Lovastatin and pravastatin on sleep and cognitive performance in patients with hypercholesterolemia. J Clin Pharmacol 1994; 34: 989-96.
20. Partinen M, Pihl S, Strandberg T, et al. Comparison of effects on sleep of lovastatin and pravastatin in hypercholesterolemia. Am J Cardiol 1994; 73: 876-80.
21. Kamei Y, Shirakawa S, Ishizuka Y, et al. Effect of pravastatin on human sleep. Psychiatry Clin Neurosci 1993; 47: 643-6.
22. Higgins J, Green S. Cochrane Handbook for systematic reviews of interventions version 5.0. 2 [updated September 2009]. The Cochrane Collaboration, 2009. wwwcochrane-handbook org/(accessed 18 May 2009). 2013.
23. Borenstein M, Hedges L, Higgins J, Rothstein H. Comprehensive meta-Analysis version 2. Englewood, NJ: Biostat 2005; 104.
24. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005; 5: 1-10.
25. Duval S, Tweedie R. Trim and fill: A simple funnel plotbased method of testing and adjusting for publication bias in meta-Analysis. Biometrics 2000; 56: 455-63.
26. Swiger KJ, Manalac RJ, Blaha MJ, Blumenthal RS, Martin SS. Statins, mood, sleep, and physical function: A systematic review. Eur J Clin Pharmacol 2014; 70: 1413-22.
27. Black DM, Lamkin G, Olivera EH, Laskarzewski PM, Stein EA. Sleep disturbance and HMG CoA reductase inhibitors. JAMA 1990; 264: 1105.
28. Ueno R, Honda K, Inoue S, Hayaishi O. Prostaglandin D2, a cerebral sleep-inducing substance in rats. Proc Natl Acad Sci USA 1983; 80: 1735-7.
29. Bielecka-Dabrowa A, Aronow WS, Rysz J, Banach M. Current place of beta-blockers in the treatment of hypertension. Curr Vasc Pharmacol 2010; 8: 733-41.
30. Galatti L, Polimeni G, Salvo F, Romani M, Sessa A, Spina E. Short-Term memory loss associated with rosuvastatin. Pharmacotherapy 2006; 26: 1190-2.
31. King DS, Wilburn AJ, Wofford MR, Harrell TK, Lindley BJ, Jones DW. Cognitive impairment associated with atorvastatin and simvastatin. Pharmacotherapy 2003; 23: 1663-7.
32. Padala KP, Padala PR, Potter JF. Simvastatin-induced decline in cognition. Ann Pharmacother 2006; 40: 1880-3.
33. Banach M, Aronow WS, Serban C, et al. Lipids, blood pressure and kidney update 2014. Pharmacol Res 2015; 95: 111-25.
34. Banach M, Mikhailidis DP, Kjeldsen SE, Rysz J. Time for new indications for statins? Med Sci Monit 2009; 15: MS1-5.
35. Banach M, Serban C, Aronow WS, et al. Lipid, blood pressure and kidney update 2013. Int Urol Nephrol 2014; 46: 947-61.